Covalent Ligand Screening Uncovers a RNF4 E3 Ligase Recruiter for Targeted Protein Degradation Applications
- ACS Chem Biol. 2019 Nov 15;14(11):2430-2440. doi: 10.1021/acschembio.8b01083.
- 1. Department of Molecular and Cell Biology , University of California, Berkeley , Berkeley , California 94720 , United States.
- 2. Novartis-Berkeley Center for Proteomics and Chemistry Technologies , University of California, Berkeley , Berkeley , California 94720 , United States.
- 3. Department of Chemistry , University of California, Berkeley , Berkeley , California 94720 , United States.
- 4. Novartis Institutes for BioMedical Research , Cambridge , Massachusetts 02139 , United States.
- 5. Novartis Institutes for BioMedical Research , Emeryville , California 94608 , United States.
- 6. Department of Nutritional Sciences and Toxicology , University of California, Berkeley , Berkeley , California 94720 , United States.
Targeted protein degradation has arisen as a powerful strategy for drug discovery allowing the targeting of undruggable proteins for proteasomal degradation. This approach most often employs heterobifunctional degraders consisting of a protein-targeting ligand linked to an E3 Ligase recruiter to ubiquitinate and MARK proteins of interest for proteasomal degradation. One challenge with this approach, however, is that only a few E3 Ligase recruiters currently exist for targeted protein degradation applications, despite the hundreds of known E3 Ligases in the human genome. Here, we utilized activity-based protein profiling (ABPP)-based covalent ligand screening approaches to identify cysteine-reactive small-molecules that react with the E3 ubiquitin Ligase RNF4 and provide chemical starting points for the design of RNF4-based degraders. The hit covalent ligand from this screen reacted with either of two zinc-coordinating cysteines in the RING domain, C132 and C135, with no effect on RNF4 activity. We further optimized the potency of this hit and incorporated this potential RNF4 recruiter into a bifunctional degrader linked to JQ1, an inhibitor of the BET family of bromodomain proteins. We demonstrate that the resulting compound CCW 28-3 is capable of degrading BRD4 in a proteasome- and RNF4-dependent manner. In this study, we have shown the feasibility of using chemoproteomics-enabled covalent ligand screening platforms to expand the scope of E3 Ligase recruiters that can be exploited for targeted protein degradation applications.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Ligands for E3 LigaseResearch Areas: Cancer
-
Research Areas: Others
-
Research Areas: Others